



ARTICLE

TRANSFORMING MUSCULOSKELETAL RESEARCH WITH REAL-WORLD EVIDENCE

AUGUST 27, 2025

www.rgnmed.com | circles@rgnmed.com

REGENMED AND OREF LAUNCH MOTIV™: A PEER-REVIEWED REAL-WORLD EVIDENCE LIBRARY FOR MUSCULOSKELETAL INNOVATION

RegenMed, in partnership with the **Orthopaedic Research and Education Foundation (OREF)**, has launched **M.O.T.I.V.™** — a pioneering initiative to generate structured, peer-reviewed, and clinically meaningful **real-world evidence (RWE)** datasets across the full spectrum of **musculoskeletal (MSK) conditions**.

MSK disorders represent one of the largest global health burdens. Nearly **one-third of the world's population** will experience an MSK-related condition in their lifetime, from degenerative joint disease and traumatic injuries to bone cancers and rare genetic disorders such as **osteogenesis imperfecta**. In the United States alone, MSK care costs are estimated to exceed **\$980 billion annually**, nearly 5% of **U.S. GDP**.

Yet despite this immense cost, outcomes for patients remain inconsistent. Scientific progress is slowed by reliance on **traditional clinical trials**, which are lengthy, expensive, and selective. Meanwhile, insurers and government payers are placing new emphasis on outcomes tracking — such as **Medicare's penalties for providers who fail to collect long-term results on hip and knee replacements**.

THE LIMITATIONS OF TODAY'S DATA

While “real-world evidence” has become a buzzword in healthcare, the vast majority of available datasets are **derived from electronic health records, insurance claims, or proprietary algorithms**. These sources, though large, are fragmented, unverifiable, and often lack correlation between diagnosis, treatment protocols, and long-term outcomes.

The result is evidence that **fails to meet clinical utility standards**, limiting its role in advancing precision care, improving health equity, or accelerating innovation.

WHAT MAKES M.O.T.I.V.™ DIFFERENT

The **M.O.T.I.V.™ (Musculoskeletal Outcomes Through Informed Validation)** program is designed to overcome these barriers. Each dataset in the library is:

- **Peer-Reviewed by OREF:** Every observational protocol is vetted by leading MSK researchers.
- **Anatomically & Clinically Specific:** Defined by one anatomical region, one pathology, one treatment protocol, and one standardized outcomes assessment.
- **Validatable to Primary Sources:** Built for transparency and trust, avoiding unverifiable big-data manipulation.
- **Longitudinal & Fit-for-Purpose:** Meeting **FDA requirements** for clinical and regulatory use.
- **Statistically and Clinically Relevant:** Designed to support meaningful insights that improve patient care.

By setting a new standard for structured, verifiable real-world data, M.O.T.I.V.™ ensures that research and innovation in orthopaedics are both clinically rigorous and widely accessible.

DRIVING VALUE-BASED CARE AND INNOVATION

The launch of M.O.T.I.V.™ marks a critical step toward achieving **value-based care** in musculoskeletal medicine. By creating datasets that are **trusted, transparent, and clinically actionable**, RegenMed and OREF are empowering:

- **Providers** to benchmark treatments and improve patient outcomes.
- **Insurers** and payers to make evidence-based reimbursement decisions.
- **Researchers** to accelerate the path from lab to bedside.
- **Patients** to benefit from more equitable, data-driven care.

This initiative positions RegenMed and OREF at the forefront of a healthcare transformation — one where **real-world evidence is no longer an aspiration, but a validated, practical tool for medical advancement.**